Abstract |
Patients with aggressive adult T-cell leukemia-lymphoma (ATL) have dismal outcomes with intensive chemotherapy. Early up-front allogeneic hematopoietic stem cell transplantation (allo-HSCT) is generally recommended. However, the choice of stem cell source, i.e., unrelated bone marrow transplant (UBMT) or cord blood transplantation (CBT), when an HLA-matched related donor is unavailable remains controversial. Thus, we undertook a decision analysis to compare the outcomes of two therapeutic strategies: chemotherapy followed by up-front UBMT at 6 months, and chemotherapy followed by up-front CBT at 3 months. Patients were stratified into low-, intermediate-, and high-risk groups according to the modified ATL-prognostic index. The model simulated life expectancy (LE) and quality-adjusted LE (QALE). LE following up-front UBMT was higher than that following up-front CBT in the low-risk group (2.63 vs. 2.28 years), but was comparable in the intermediate- (2.06 vs. 2.01 years) and high-risk groups (1.25 vs. 1.30 years). The Monte Carlo simulation for LE and QALE in each risk group showed that there was significant uncertainty in all categories. In conclusion, up-front UBMT was superior to up-front CBT in the low-risk group, but the strategies were comparable in the intermediate- and high-risk groups.
|
Authors | Shigeo Fuji, Saiko Kurosawa, Yoshihiro Inamoto, Tatsunori Murata, Atae Utsunomiya, Kaoru Uchimaru, Satoshi Yamasaki, Yoshitaka Inoue, Yukiyoshi Moriuchi, Ilseung Choi, Masao Ogata, Michihiro Hidaka, Takuhiro Yamaguchi, Takahiro Fukuda |
Journal | International journal of hematology
(Int J Hematol)
Vol. 111
Issue 3
Pg. 427-433
(Mar 2020)
ISSN: 1865-3774 [Electronic] Japan |
PMID | 31701480
(Publication Type: Comparative Study, Journal Article)
|
Topics |
- Adult
- Aged
- Allografts
- Bone Marrow Transplantation
- Decision Support Techniques
- Disease Progression
- Female
- Fetal Blood
(transplantation)
- Humans
- Leukemia-Lymphoma, Adult T-Cell
(therapy)
- Male
- Middle Aged
- Prognosis
- Risk
|